AccuImage Names Robert Taylor CEO.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 4, 1999--

AccuImage Diagnostics Corporation announced today that Robert Taylor, Ph.D. has been appointed CEO. Dr. Taylor was previously company COO and succeeds the former CEO Dr. Allen Poirson who has resigned.

According to Dr. Douglas Boyd, Chairman of the Board, "Dr. Taylor's appointment brings strong leadership at a key point in the development of AccuImage. Our 3D Workstation product, AccuView, and its Web-based eStation3D counterpart demand focused marketing and active operational support, areas in which Robert excels."

The company has recently completed an advanced suite of 3D post-processing and connectivity software for medical imaging applications (primarily CT, MRI and Ultrasound) which has been in development since late 1997. AccuImage software provides review and analysis tools to medical professionals, and provides for the transfer of medical images across the Internet and hospital Intranets.

Dr. Taylor will take the maturing 3D Workstation product to its market while continuing to spearhead the development of the eStation3D. eStation3D is a web-capable PACS/Teleradiology product, augmented by selected advanced post-processing techniques harvested from the AccuImage 3D Workstation.

Dr. Taylor's former career as a physicist resulted in numerous refereed publications on his computational and experimental research, particularly in the realm of 3D simulation and visualization. He also has over ten years' experience of commercial software development in a broad range of settings, from healthcare systems to computer games. He received both his B.Sc. (1990) and his Ph.D. (1996) in physics from Imperial College in London, England.

AccuImage workstations are installed at leading hospitals and clinics internationally, including UCSF, UCLA, The Mayo Clinic, Stanford University, Department of Veteran Affairs Medical Center, San Francisco University of Munich, Singapore National University, Youngsei Hospital, University of Graz, HeartScan USA, and others.

AccuImage's success to date in providing Imatron Inc. (Nasdaq:IMAT) with the Workstation component of their EBT scanner is a model the company seeks to apply to the medical imaging market as a whole.

AccuImage, a public company, recently completed and filed with the SEC a Form 10-SB, which is currently under review. The company intends to complete this review process, and should the filing reach a state of "No further comment" from the SEC, AccuImage would be in compliance with the recently introduced OTC-BB Eligibility Rule.

AccuImage is committed to achieving this goal, in order that the company may apply for re-listing on the NASD OTC Electronic Bulletin Board. The company's shares are currently traded on the pink sheets through NASD market makers.

Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industry in which AccuImage operates, the estimated impact of certain technological advances, as well as management's beliefs and assumptions. It is important to note that the company's actual results could differ materially from those projected in such forward-looking statements. The factors that could cause actual results to differ materially include, among others: reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; and the risk factors listed from time to time in the company's Securities and Exchange Commission reports.